Recently, Faricimab (Vabysmo), a bispecific antibody targeting both VEGF-A and ANG-2 [66], has been approved by the FDA, for the treatment of AMD and diabetic macular edema. This evidence concerns the gene VEGFA and age-related macular degeneration.